keyword
MENU ▼
Read by QxMD icon Read
search

Ceftolozane tazobactam

keyword
https://www.readbyqxmd.com/read/29649276/carbapenem-resistant-gram-negative-pathogens-in-a-german-university-medical-center-prevalence-clinical-implications-and-the-role-of-novel-%C3%AE-lactam-%C3%AE-lactamase-inhibitor-combinations
#1
Juri Katchanov, Lucia Asar, Eva-Maria Klupp, Anna Both, Camilla Rothe, Christina König, Holger Rohde, Stefan Kluge, Florian P Maurer
OBJECTIVES: To determine the spectrum of infections with multidrug-resistant Gram-negative bacteria (MDR-GNB) and the clinical impact of the newly available betalactam/betalactamase inhibitor combinations ceftolozane/tazobactam and ceftazidime/avibactam in a German academic tertiary care center. METHODS: Retrospective analysis. RESULTS: Between September 1, 2015 and August 31, 2016, 119 individual patients (0.22% of all hospital admissions) were colonized or infected with carbapenem-resistant MDR-GNB...
2018: PloS One
https://www.readbyqxmd.com/read/29621591/bacteraemia-due-to-extensively-drug-resistant-pseudomonas-aeruginosa-sequence-type-235-high-risk-clone-facing-the-perfect-storm
#2
Raúl Recio, Jennifer Villa, Esther Viedma, María Ángeles Orellana, Jaime Lora-Tamayo, Fernando Chaves
Predictors of mortality and the impact of multidrug resistance and virulence on patients with Pseudomonas aeruginosa (PA) bacteraemia were evaluated. Patients with PA bacteraemia in a 12-month period were retrospectively analysed. Carbapenemase production, molecular typing and identification of virulence factor ExoU were carried out. The activity of ceftolozane-tazobactam and ceftazidime-avibactam was also investigated. The primary endpoint was 30-day crude mortality. Of 64 patients with bacteraemia, 24 (37...
April 2, 2018: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29596902/ceftolozane-tazobactam-dose-regimens-in-severely-morbidly-obese-patients-with-complicated-intra-abdominal-infection-or-complicated-urinary-tract-infection
#3
Alan J Xiao, Jennifer A Huntington, Jianmin Long, Luzelena Caro
INTRODUCTION: Ceftolozane/tazobactam is approved for the treatment of complicated intra-abdominal infection (cIAI) and complicated urinary tract infection (cUTI) with renal function-based dose adjustment. Given that creatinine clearance, body weight and gender are highly correlated in severely/morbidly obese patients, this study investigated whether the approved dosing regimens for ceftolozane/tazobactam are also appropriate in severely/morbidly obese patients based on simulated pharmacokinetic/pharmacodynamic target attainment, with confirmation from the observed clinical outcomes data from the phase 3 clinical development program...
March 26, 2018: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29594953/ceftolozane-tazobactam-for-the-treatment-of-xdr-pseudomonas-aeruginosa-infections
#4
Laura Escolà-Vergé, Carles Pigrau, Ibai Los-Arcos, Ángel Arévalo, Belen Viñado, David Campany, Nieves Larrosa, Xavier Nuvials, Ricard Ferrer, Oscar Len, Benito Almirante
PURPOSE: The aim of this study was to evaluate the effectiveness of ceftolozane/tazobactam (C/T) for treating extensively drug-resistant Pseudomonas aeruginosa (XDR-PA) infections, and to analyze whether high C/T dosing (2 g ceftolozane and 1 g tazobactam every 8 h) and infection source control have an impact on outcome. METHODS: Retrospective study of all consecutive patients treated with C/T for XDR-PA infection at a tertiary referral hospital (November 2015-July 2017)...
March 28, 2018: Infection
https://www.readbyqxmd.com/read/29580930/what-non-carbapenem-antibiotics-are-active-against-esbl-producing-enterobacteriaceae
#5
Hélène Bouxom, Damien Fournier, Kevin Bouiller, Didier Hocquet, Xavier Bertrand
We evaluated the activity of 18 non-carbapenem antibiotics on 100 ESBL-producing Escherichia coli (ESBL-Ec) and 50 ESBL-producing Klebsiella pneumoniae (ESBL-Kp) isolated from urinary tract infections and bacteremia in 2016. MICs were determined using reference methods and susceptibility profiles were defined according to the EUCAST 2017 recommendations. All the ESBL-Ec isolates were susceptible to ceftazidime-avibactam and a great majority of them were susceptible to fosfomycin (98%), piperacillin-tazobactam (97%), amikacin (97%) and nitrofurantoin (96%)...
March 23, 2018: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/29559421/in-vitro-antimicrobial-activity-of-ceftolozane-tazobactam-against-p-aeruginosa-and-other-non-fermenting-gram-negative-organisms-in-adults-with-cystic-fibrosis
#6
A Gramegna, B C Millar, F Blasi, J S Elborn, D G Downey, J E Moore
INTRODUCTION: Pulmonary exacerbations in people with Cystic Fibrosis (CF), with chronic Gram-negative pathogens, are associated with reduced survival. These pathogens are usually treated with repeated courses of systemic antibiotics. However there is a linked emergence of multidrug resistant (MDR) pathogens. Ceftolozane/tazobactam is a new cephalosporin/beta-lactamase inhibitor combination that has been demonstrated to have good activity against MDR Pseudomonas aeruginosa. MATERIAL & METHODS: In this study ceftolozane/tazobactam was compared to other commonly used intravenous antibiotics against 193 non-fermenting Gram-negative bacteria isolated from CF sputum specimens, including P...
March 17, 2018: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/29530842/evaluation-of-ceftolozane-tazobactam-in-combination-with-meropenem-against-pseudomonas-aeruginosa-st175-in-a-hollow-fiber-infection-model
#7
M Montero, Brian D VanScoy, Carla López-Causapé, Haley Conde, Jonathan Adams, Concepción Segura, Laura Zamorano, Antonio Oliver, Juan P Horcajada, Paul G Ambrose
The aim of this study was to investigate the efficacy of ceftolozane-tazobactam in combination with meropenem against an extensively drug-resistant (XDR) Pseudomonas aeruginosa high-risk clone, ST175, isolated in a Spanish university hospital. A 14-day hollow-fiber infection model was used to simulate clinical exposure of the 2 drug regimens alone and in combination, and serial samples were collected to determine drug concentrations and colony-forming unit (CFU) counts. The untreated control failed, as did each study regimen when administered alone...
March 12, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29521242/ceftazidime-avibactam-and-ceftolozane-tazobactam-novel-therapy-for-multidrug-resistant-gram-negative-infections-in-children
#8
David P Nicolau, Brittany A Rodrigueza, Jennifer E Girottoa
The rise in multidrug-resistant (MDR) infections has become a significant problem in both the developing countries and in the United States (U.S.). Specifically, MDR gram-negative infections are emerging, affecting not only adults but children as well. The specific gram-negative organisms that have been most concerning within the pediatric population include MDR P. aeruginosa, Enterobacteriaceae, and Acinetobacter spp. The increase in antimicrobial resistance rates are associated with various mechanisms, with, one of the most common being the production of beta-lactamases...
March 8, 2018: Current Pediatric Reviews
https://www.readbyqxmd.com/read/29517862/safety-tolerability-and-pharmacokinetics-of-3-g-of-ceftolozane-tazobactam-in-healthy-adults-a-randomized-placebo-controlled-multiple-dose-study
#9
Brian Yu, Adedayo Adedoyin, Ellie Hershberger, Luzelena Caro, Alan Xiao, Elizabeth G Rhee, Jennifer A Huntington
Ceftolozane/tazobactam is an antibacterial approved at 1.5 g (1g/0.5 g) every 8 hours (q8h); higher doses may provide additional benefits in difficult-to-treat infections. We conducted a phase I trial in healthy adults evaluating safety, tolerability, and pharmacokinetics of 3 g (2 g/1 g) ceftolozane/tazobactam administered q8h for 10 days. Sixteen participants were randomized (2:1:1) to 3 g ceftolozane/tazobactam, 1.5 g ceftolozane/tazobactam, or placebo. Participants underwent regular safety and plasma drug level assessments, with a follow-up safety visit 7 days after completion...
March 8, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29493397/ceftolozane-tazobactam-place-in-therapy
#10
Daniele Roberto Giacobbe, Matteo Bassetti, Francesco Giuseppe De Rosa, Valerio Del Bono, Paolo Antonio Grossi, Francesco Menichetti, Federico Pea, Gian Maria Rossolini, Mario Tumbarello, Pierluigi Viale, Claudio Viscoli
Ceftolozane/tazobactam (C/T) is a new antibiotic resulting from the combination of a novel cephalosporin, structurally similar to ceftazidime, with tazobactam, a well-known beta-lactamase inhibitor. C/T remains active against extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae and multi-drug resistant (MDR) P. aeruginosa, and has been recently approved for the treatment of complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI). A trial on hospital-acquired pneumonia is ongoing...
March 9, 2018: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/29483119/efficacy-of-human-simulated-exposures-of-ceftolozane-tazobactam-alone-and-in-combination-with-amikacin-or-colistin-against-multidrug-resistant-pseudomonas-aeruginosa-in-an-in-vitro-pharmacodynamic-model
#11
V Rico-Caballero, Safa Almarzoky Abuhussain, Joseph L Kuti, David P Nicolau
Combination therapy is an attractive option for the treatment of multidrug resistant (MDR) Pseudomonas aeruginosa infections; however, limited data are available on combinations with ceftolozane/tazobactam (C/T). The in vitro pharmacodynamic chemostat model was employed to compare human simulated exposures of C/T 3g q8h alone or in combination with amikacin 25 mg/kg daily or colistin 360 mg daily against four MDR P. aeruginosa isolates. C/T alone resulted in 24 hour CFU changes of -0.02±0.21, -1.81±0.55, -1...
February 26, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29483111/-in-vitro-susceptibility-of-ceftolozane-tazobactam-against-burkholderia-pseudomallei
#12
Elaine Chan, Paolo Martelli, Suk-Wai Hui, Jade L L Teng, Susanna K P Lau, Patrick C Y Woo
Burkholderia pseudomallei is the cause of melioidosis, a potentially serious and fatal disease characterized by community-acquired pneumonia and/or sepsis mainly in Southeast Asia and Northern Australia, and high case-fatality rates of up to 19% are observed in endemic areas (1).
February 26, 2018: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/29460229/ceftolozane-tazobactam-therapy-for-multidrug-resistant-pseudomonas-aeruginosa-infections-in-patients-with-hematologic-malignancies-and-hematopoietic-cell-transplant-recipients
#13
Morgan Hakki, James S Lewis
Multidrug-resistant (MDR) Pseudomonas aeruginosa infection causes significant mortality among patients with hematologic malignancies and hematopoietic-cell transplant recipients. Ceftolozane-tazobactam (C-T) is a novel therapeutic option for MDR-P. aeruginosa infections but clinical experience in these patients is limited. We report favorable clinical outcomes and lack of limiting toxicities using C-T monotherapy to treat invasive MDR-P. aeruginosa infections in these patient populations.
February 19, 2018: Infection
https://www.readbyqxmd.com/read/29402125/management-of-infections-caused-by-extended-spectrum-%C3%AE-lactamase-producing-enterobacteriaceae-current-evidence-and-future-prospects
#14
Chau-Chyun Sheu, Shang-Yi Lin, Ya-Ting Chang, Chun-Yuan Lee, Yen-Hsu Chen, Po-Ren Hsueh
The spread of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae has become a major public health threat worldwide. Area covered: A thorough systematic literature review describing the current evidence and future prospects of therapeutic options for infections caused by ESBL-producing Enterobacteriaceae. Expert commentary: The methods of detecting ESBLs have been evolving. The Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing lowered the MIC breakpoints of cephalosporins against ESBL-producing Enterobacteriaceae in 2010...
March 2018: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/29378381/-antimicrobial-activity-of-ceftolozane-tazobactam-against-enterobacteriaceae-and-pseudomonas-aeruginosa-in-the-czech-republic-in-2016
#15
Helena Žemličková, Vladislav Jakubů, Marta Fridrichová
OBJECTIVE: Ceftolozane/tazobactam is an antibiotic effective against Gram-negative bacteria(including Pseudomonas aeruginosa).The study aimed at determining the effectiveness of the novel antibiotic in the Czech Republic. MATERIAL AND METHODS: The effectiveness of the antibiotic was studied in 16 Czech laboratories in 822 Enterobacteriaceae isolates (including AmpC and ESBL producers) and P. aeruginosa causing complicated intraabdominal or urinary tract infections...
December 2017: Klinická Mikrobiologie a Infekc̆ní Lékar̆ství
https://www.readbyqxmd.com/read/29366723/clinical-experience-with-ceftolozane-tazobactam-in-patients-with-serious-infections-due-to-resistant-pseudomonas-aeruginosa
#16
Marc Xipell, Sandra Paredes, Leticia Fresco, Marta Bodro, Francesc Marco, J A Martínez, Alex Soriano
The incidence of infections caused by multidrug resistant Pseudomonas aeruginosa (MDR-PA) has become a concern of increasing relevance nowadays. Ceftolozane/tazobactam is a novel 5th generation cephalosporin/β-lactamase inhibitor combination with activity against MDR-PA.
January 20, 2018: Journal of Global Antimicrobial Resistance
https://www.readbyqxmd.com/read/29337703/new-antibiotics-for-ventilator-associated-pneumonia
#17
Matteo Bassetti, Antionio Vena, Nadia Castaldo, Elda Righi, Maddalena Peghin
PURPOSE OF REVIEW: Ventilator-associated pneumonia (VAP) caused by multidrug-resistant (MDR) bacteria represents a global emerging problem. Delayed prescription of an adequate treatment for VAP has been associated with higher morbidity and mortality. New molecules have been developed to face the need of compounds that are active against resistant Gram-positive and Gram-negative pathogens. The aim of this review is to summarize the current scenario of new therapeutic options for the treatment of VAP...
April 2018: Current Opinion in Infectious Diseases
https://www.readbyqxmd.com/read/29305368/treatment-of-a-complex-orthopaedic-infection-due-to-extensively-drug-resistant-pseudomonas-aeruginosa
#18
Sidra Hassan, Mani D Kahn, Nidhi Saraiya, Priya Nori
According to the Centers for Disease Control and Prevention (CDC), approximately 51 000 healthcare-associated infections caused by Pseudomonas aeruginosa occur annually in the USA, more than 6000 of which (13%) are caused by multidrug resistant (MDR) strains. Ceftolozane/tazobactam (TOL/TAZ) (Zerbaxa) was approved by the US Food and Drug Administration (FDA) in December 2014 for the treatment of complicated intra-abdominal and urinary tract infections. At this time, clinical data on the role of TOL/TAZ treatment outside of FDA-approved indications is limited...
January 5, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29244121/in-vitro-activity-of-ceftolozane-tazobactam-versus-antimicrobial-non-susceptible-pseudomonas-aeruginosa-clinical-isolates-including-mdr-and-xdr-isolates-obtained-from-across-canada-as-part-of-the-canward-study-2008-16
#19
Andrew Walkty, Heather Adam, Melanie Baxter, Philippe Lagacé-Wiens, James A Karlowsky, Daryl J Hoban, George G Zhanel
Objectives: Ceftolozane/tazobactam is a novel β-lactam β-lactamase inhibitor combination with a broad spectrum of activity that includes Pseudomonas aeruginosa. The purpose of this study was to evaluate the in vitro activity of ceftolozane/tazobactam and relevant comparators versus a large collection of antimicrobial non-susceptible P. aeruginosa clinical isolates recovered from patients across Canada (CANWARD, 2008-16). Methods: Susceptibility testing was performed on P...
December 12, 2017: Journal of Antimicrobial Chemotherapy
https://www.readbyqxmd.com/read/29228202/activity-of-ceftazidime-avibactam-against-problem-enterobacteriaceae-and-pseudomonas-aeruginosa-in-the-uk-2015-16
#20
David M Livermore, Danièle Meunier, Katie L Hopkins, Michel Doumith, Robert Hill, Rachel Pike, Peter Staves, Neil Woodford
Background: Ceftazidime/avibactam combines an established oxyimino-cephalosporin with the first diazabicyclooctane β-lactamase inhibitor to enter clinical use. We reviewed its activity against Gram-negative isolates, predominantly from the UK, referred for resistance investigation in the first year of routine testing, beginning in July 2015. Methods: Isolates were as received from referring laboratories; there is a bias to submit those with suspected carbapenem resistance...
December 8, 2017: Journal of Antimicrobial Chemotherapy
keyword
keyword
118181
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"